Sun Pharma Advanced Research Company (SPARK) reported a net loss of Rs 63.16 crore in Q2 September 2019, higher than net loss of Rs 2.58 crore Q2 September 2018.
Revenue from operations slumped 71.98% to Rs 17.19 crore in Q2 September 2019 over Q2 September 2018.
The stock fell as much as 5.48% to hit an intraday low of Rs 135.50. The stock was currently trading higher by 1.85% at Rs 146.
On the BSE, 3.96 lakh shares were traded in the counter so far compared with average daily volumes of 1.29 lakh shares in the past two weeks. The stock hit a high of Rs 151.9 so far during the day.
Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
